


Development of a biologic for cancer therapy that targets the TWEAK receptor Fn14 with a mutated variant of the serine protease granzyme B as the cytotoxic payload



Authors:

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Timothy G. Whitsett, Jeffrey A Winkles, Walter N. Hittelman and Michael G. Rosenblum

Correspondence:

Ana Alvarez-Cienfuegos

In brief:

GrB(C210A)-Fc-IT4 is a fusion construct that delivers a genetically modified version of GrB into the cytoplasm of tumor cells expressing Fn14, and activating different apoptotic pathways. GrB(C210A)-Fc-IT4 demonstrates excellent, specific cytotoxicity *in vitro* and impressive *in vivo* efficacy with no significant toxicity in normal murine models.